Learn pulmonary hypertension with a Medcomic
Pulmonary hypertension (PH) refers to increased pressure in the pulmonary circulation. It develops when pulmonary vessels become constricted and/or obstructed, which can occur in a wide variety of conditions. The increase in pressure is measured by right catheterization, and is defined as a mean pulmonary arterial pressure ? 25 mm Hg at rest.
Scleroderma Patients with Lung Conditions Have Shorter Lifespans, Need Better Therapies, Study Reports
Scleroderma patients with lung diseases have shorter lifespans than those without pulmonary conditions, underscoring the need for better treatments for patients with lung conditions, a Colorado study reports.
Year-end Letter 2017
2017 has been a PHenomenal year for our community; from hosting the first annual PHA Canada Regional PH Symposium, to smashing through our November Life in Purple Challenge fundraising target, we have a lot to celebrate!
PHAC AMBASSADOR REPORT: “Giving Canada’s Health Care System a 21st-century overhaul”
As a recently appointed Ambassador for PHA Canada, Joan has committed herself to acting as a lifeline for newly diagnosed patients, and hopes to remain a strong advocate for making necessary treatments available for those who need them. And so we sent Joan on a mission to the 2017 CORD Conference in Toronto last month to represent the PH community: here is her personal report.
Aftermath of a blood clot brings deadly pressure in the lungs
When he couldn’t trek through woods and hills near a family cabin in Allegheny National Forest to get to the best spots for fly-fishing, Richard Faix of Monroeville said he knew his shortness of breath was serious. “I was tired of people telling me I had asthma,” said Mr. Faix, 63, an ultrasound imaging specialist. He got a new pulmonologist, who ordered a CAT scan and a pulmonary function test.
Health Canada gives 'kiss of death' to planned policy for rare-disease drugs
OTTAWA — Health Canada has quietly deleted from its website all references to a planned framework for rare-disease drugs that dates back to 2012 and was intended to improve the availability of such drugs in Canada. Canada is one of the only developed countries without a regulatory framework for rare-disease drugs, also known as orphan drugs.
Balloon pulmonary angioplasty may improve hemodynamic results in CTEPH
Balloon pulmonary angioplasty may be a viable option for patients with chronic thromboembolic pulmonary hypertension who were ineligible for pulmonary endarterectomy, according to results from a multicenter registry.
PDE5 Blocker May Be an Effective Therapy for Early PH After Heart Attack, Study Suggests
Blocking the enzyme phosphodiesterase 5 (PDE5) is a potential new therapeutic strategy to treat early pulmonary hypertension (PH) in patients who have had a heart attack, a study suggests. The research, “Pulmonary vasodilation by phosphodiesterase 5-inhibition is enhanced and nitric oxide-independent in early pulmonary hypertension after myocardial infarction,” was published in the The American Journal of Physiology-Heart and Circulatory Physi…
OHIP+: Children and Youth Pharmacare: An update on public drug coverage for PH medications for youth in Ontario
Earlier this year, the government of Ontario announced the expansion of the Ontario Health Insurance Program (OHIP) to include coverage of all children and youth aged 24 and younger. Starting January 01, 2018, drug products currently available through the Ontario Drug Benefit Program will be free to everyone under the age of 25. Medications currently available through the Exceptional Access Program – including treatments for pulmonary hypertensio…
Legacy of Alberta girl with rare disease lives on in new documentary
She died much too early, but an Edmonton girl continues to brighten lives after her passing. Her family is making sure her legacy lives on in a new documentary. Su-Ling Goh has Sophia Syskakis' story.
Recent News


Get the latest on PH treatments, community events and more when you subscribe to our newsletter